Clinical heart failure, restrictive cardiomyopathy, and arrhythmias are hallmark features of amyloid cardiomyopathy. In contrast to the advancements in targeted therapies, there is a general lack of evidence-based practice guidelines for clinical management of amyloid cardiomyopathy. In this review, we review the role of routine medical therapy in amyloid cardiomyopathy, from heart failure management to orthostatic hypotension, atrial arrhythmias, thromboembolic complications, and prevention of sudden death. We conclude by discussing approaches to patients with end-stage disease.

中文翻译：

---

淀粉样蛋白心肌病的临床治疗

临床心力衰竭、限制性心肌病和心律失常是淀粉样蛋白心肌病的标志性特征。与靶向治疗的进步相比，淀粉样蛋白心肌病临床管理普遍缺乏循证实践指南。在这篇综述中，我们回顾了常规药物治疗在淀粉样蛋白心肌病中的作用，从心力衰竭管理到体位性低血压、房性心律失常、血栓栓塞并发症和预防猝死。最后，我们讨论了治疗终末期疾病患者的方法。